Medscape | Boxed warning for HBV risk added to Rituxan, Arzerra Clinical Advisor The FDA has announced that the anti-CD20-directed monoclonal antibodies rituximab (Rituxan) and ofatumumab (Arzerra) will carry a boxed warning for immunosupression-related reactivation of hepatitis B virus (HBV) in a drug safety communication. Boxed Warning on HBV Reactivation for Blood Cancer Drugs FDA updates 'box warning' for Arzerra and Rituxan to include Hepatitis B ... Boxed warning for potential HBV reactivation added to Arzerra, Rituxan labeling |
